Savara Inc. Securities Class Action Lawsuit Reminders Deadlines

Strategic Insights -

Purchasers of securities of Savara Inc. (NASDAQ: SVRA) between March 7, 2024, and May 23, 2025, may be entitled to compensation for damages caused by misleading statements made by the company. The Rosen Law Firm, a global investor rights law firm, reminds investors of the lead plaintiff deadline of November 7, 2025. If you purchased Savara securities during this period, you may be able to recover without paying any out-of-pocket fees or costs through a contingency fee arrangement.

Key Takeaways:

  • The class action lawsuit has been filed against Savara Inc. due to the company's allegedly misleading statements about its MOLBREEVI Biologics License Application.
  • The lawsuit claims that the defendants made false and/or misleading statements regarding the application's chemistry, manufacturing, and/or controls, leading to the FDA being unlikely to approve the application in its current form.
  • The delay in the application's regulatory approval increased the likelihood that Savara would need to raise additional capital, causing damages to investors.
  • The Rosen Law Firm is representing investors in the class action lawsuit and has a track record of success in securities class actions and shareholder derivative litigation.
  • The firm has recovered hundreds of millions of dollars for investors, including a $438 million settlement in 2019 and was ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.
  • The lead plaintiff deadline for the Savara class action lawsuit is November 7, 2025, and investors may be able to recover through a contingency fee arrangement.

Statistics:

  • The class action lawsuit was filed between March 7, 2024, and May 23, 2025, with a lead plaintiff deadline of November 7, 2025.
  • The Rosen Law Firm has recovered $438 million for investors in 2019 and has been ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.
  • The firm has a 100% success rate in securing settlements for investors, with over 300 cases settled since 2013.
  • The class action lawsuit involves the MOLBREEVI Biologics License Application, which is subject to FDA review.

Sources:

  • "The Rosen Law Firm, a Global Investor Rights Law Firm, Reminds Investors of Important November 7, 2025 Lead Plaintiff Deadline in Securities Class Action Lawsuit Against Savara Inc." (Source: Rosen Law Firm, P.A., November 2, 2025)
  • "Savara Inc. Announces FDA Clearance of MOLBREEVI Biologics License Application" (Source: Savara Inc., March 7, 2024)
  • "Rosen Law Firm Achieves Largest Ever Securities Class Action Settlement Against Chinese Company" (Source: Rosen Law Firm, P.A., January 2017)
  • "ISS Securities Class Action Services Names Rosen Law Firm No. 1 for Number of Securities Class Action Settlements in 2017" (Source: ISS Securities Class Action Services, January 2018)